Soft Tissue Sarcoma Market Size (2025-2030)

The Global Soft Tissue Sarcoma Market was valued at USD 1.58 billion in 2024 and is projected to reach a market size of USD 2.57 billion by the end of 2030. Over the forecast period of 2025-2030, the market is projected to grow at a CAGR of 10.21%. 

Positive trends in the soft tissue sarcoma market are currently being observed that will drive growth during the forecast period. There is a surge in investment in R&D activities related to drug development for better treatment options. In addition, growing government support for cancer research and awareness about soft tissue sarcoma is also fueling the market growth. There are several pharmaceutical companies that are very keen on the development of new drugs and combination therapies to effectively treat soft tissue sarcoma, thereby driving the market. In addition, improving healthcare infrastructure and access to therapies worldwide presents a promising opportunity over the next few years.

Key Market Insights:

• The market for treatments of soft tissue sarcoma would experience tremendous growth due to disease incidence and a rise in newer therapeutic options available. However, the challenges the market may pose include high-cost treatment and, more importantly, a lack of awareness in most developing regions to expand the scope of the market.
• In March 2024, Pfizer reported the positive results of a phase III trial for its new immunotherapy drug. In June 2023, Eli Lilly bought a small biotech firm specializing in targeted therapies that would add to its pipeline for soft tissue sarcoma.
• The signs and symptoms of STS vary significantly according to the type of tumor. However, in the case of STS, a patient might have a progressively enlarging painless mass in the affected area. The increasing rate of diagnosis of soft tissue sarcoma will fuel the market growth. The American Society of Clinical Oncology (ASCO) estimates.
• Nearly about 13,130 people will be diagnosed in the US, with an approximate figure for this year 2020. A better medical technological advancement increases public awareness about such diseases, which, in combination with the advent of effective drug treatments, might fuel the development of the market for STS.

Soft Tissue Sarcoma Market Drivers:

Increasing Incidences of Soft Tissue Sarcoma is Driving the Market Growth.

Incidences According to the American Cancer Society, an estimated 13,400 new cases of soft tissue sarcoma will be diagnosed in 2023. Of this number, about 7,400 new cases are expected among males and about 6,000 among females. In addition, it is estimated that during the same year, about 5,000 people will probably die from soft tissue sarcomas. The high incidence of the disease is associated with the growing patient population, which ultimately increases the demand for related therapeutics, providing a background for market growth. Major causes of lethality of soft tissue sarcomas are delayed diagnosis and advanced disease or metastasis stage. Around 60% of sarcomas are found as localized sarcoma, 18% of them are seen in a locally advanced stage, and about 15% are diagnosed in the metastatic stage.

The majority of players in the soft tissue sarcoma market are aiming to develop novel drugs and therapies.

The majority of the players in the soft tissue sarcoma market intend to develop innovative drugs and therapies for the management of advanced-stage soft tissue sarcoma. In this respect, the market receives a strong pipeline from the giants as well as the start-ups. This clinical research paves the way to effective treatment and serves as a precursor to the expansion of the market. Besides, favorable reimbursement policies are major considerations for growth in the STS market. Drugs like Yondelis and Halaven are reimbursable. For instance, Yondelis is identified with a permanent, drug-specific HCPCS code J9352 and was registered on the National Health Insurance (NHI) reimbursement price list in Japan in 2015, with a reimbursement price of about USD 459.73 for 0.25mg and USD 1843.31 for 1mg of the drug. This is increasing the buying capacity of the patient as the patient can now pay out-of-pocket expenses.

Increasing prevalence of soft tissue sarcoma globally.

The incidence rates of soft tissue sarcomas have been rising steadily over the past few decades in different countries and regions of the world. Several epidemiological studies have suggested an increase in the incidence of soft tissue cancers, particularly in developed Western countries with higher life expectancies. The overall aging global population profile is one of the major contributing factors to the increasing prevalence rates. In contrast, increased lifespan through advanced public healthcare and advances in medical technology increase the predisposition to later life-onset cancers of a variety of histologies. In general, soft tissue sarcomas have always been diagnosed at a greater prevalence in the demographic groups older in age.

Soft Tissue Sarcoma Market Restraints and Challenges:

The treatment cost is high and some commercial drugs are showing adverse events.

One of the major challenges in the market includes the high prices of STS therapies due to the cost of research and development, the cost of developing equipment, the cost of radiation therapy and surgery, and the cost of insurance. For example, the cost of the third line and second line of treatment for STS is estimated to be over USD 20,000 and USD 10,000. This is a threat to the adoption of treatments available in the market, thus creating a hindrance to market growth in the future. Further, most of the commercial drugs also have low adverse events recorded in STS treatment. For example, Eli Lilly reported in 2019 that Lartruvo poses fetal harm when a pregnant woman takes it, and Eli Lilly repressed the drug from the market. This therefore builds up unwillingness in the patient to take the treatment, which limits the growth of the market.

Soft Tissue Sarcoma Market Opportunities:

One of the greatest opportunities is the patient pool rise in emerging economies of the Asia-Pacific region. Soft-tissue sarcomas have always been less common in Asia than in Western countries, but there is a tremendous development in healthcare infrastructure and standards of treatment of cancer across Asia-Pacific. This has led to a greater rate of soft-tissue sarcoma diagnosis. Countries like China, India, Japan, and South Korea now represent the bulk of the global soft tissue sarcoma incidence. Asia-Pacific is also witnessing rapid economic growth, higher healthcare spending capabilities, and rising medical tourism. All these factors are supporting increased investments in advanced diagnostic technologies, specialty surgical facilities, and innovative oncology treatments in the region.

 The soft tissue sarcoma market provides an attractive opportunity for players to expand into the developing Asia-Pacific markets and garner more significant revenue shares. Collaboration with hospitals and other medical establishments in Asia will assist companies in improving early diagnosis rates and launching new drugs and equipment at affordable prices. This provides opportunities for sustainable leadership in the global soft tissue sarcoma domain over the next few years.

SOFT TISSUE SARCOMA MARKET REPORT COVERAGE:

Soft Tissue Sarcoma Market Segmentation:

Soft Tissue Sarcoma Market Segmentation: Treatment Type

• Chemotherapy
• Targeted Therapy
• Immunotherapy

Chemotherapy sub-segment accounts for the highest share of 45.3% in the market as it is highly effective and accepted. Chemotherapy is still the most used treatment type for soft tissue sarcoma due to its proven efficacy and acceptance by both patients and physicians. Many chemotherapy drugs have been approved and utilized to treat various types and stages of soft tissue sarcoma. Drugs such as doxorubicin, ifosfamide, and dacarbazine are used either alone or in combination: have demonstrated response rates in soft tissue sarcoma and become the standard first-line treatment options. The advantages of chemotherapy include response rates and increased survival time even in advanced and metastatic diseases that outweigh the risks of toxic effects for most patients. There is also awareness from physicians' ends on the administration, monitoring, and management of chemotherapy as well as response and side effects in patients. Established treatment protocols make it easier for oncologists to prescribe chemotherapy confidently in soft tissue cases of sarcoma.

Soft Tissue Sarcoma Market Segmentation: By End-User (Hospitals, Specialty Clinics)

• Hospitals
• Specialty Clinics

Hospitals sub-segment accounts for the highest share of 61.2% among end-users because of access to multidisciplinary cancer care and comprehensive treatment approaches. Access to multidisciplinary soft tissue cancer care teams consisting of medical oncologists, surgeons, radiologists, pathologists, and other specialists drives many soft tissue sarcoma patients, especially those with advanced disease, to seek treatment in hospitals. Coordination among multiple specialists, where complex workup of patients occurs, requires finding optimal plans combining different multimodal local as well as systemic treatments. The medical facilities are well-equipped for highly aggressive treatment schedules, including surgeries such as limb salvage procedures accompanied by chemotherapy and radiation. In addition, such hospitals have appropriate intensive care and continuous monitoring for the management of postoperative treatment and side effects. Regional cancer centers and specialized sarcoma units in more extensive hospitals are also available and provide access to clinical trials, new treatments, and other therapeutic advancements. Seamless delivery of comprehensive sarcoma care can be achieved through the concentration of cancer specialists, state-of-the-art diagnostic technologies, surgical facilities, and all other necessary infrastructure in the hospital setup, attracting even locally advanced cases seeking multidisciplinary expertise under one roof. It ensures continuity of care through all phases from diagnosis to survivorship. With hospitals showing improvement in clinical results due to their multidisciplinary cancer programs, their patronage is steadily rising. This would further cement hospitals' position among the leading end-users of treatment for soft tissue sarcoma patients in the following years.

Soft Tissue Sarcoma Market Segmentation: Regional Analysis:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

North America is the largest region in the global soft tissue sarcoma market, holding a significant share of the market revenue. The growth in this region is due to factors such as the high prevalence of soft tissue sarcoma, the availability of advanced healthcare infrastructure, favorable reimbursement policies, and the presence of major market players. According to the American Cancer Society, there are around 13,000 newly diagnosed soft tissue sarcoma cases in the United States each year. Rising incidence is mainly contributed to by factors such as aging population and lifestyle changes. Additionally, with the advanced diagnostic technologies now available in North America, such as MRI and CT scans, patients are diagnosed at earlier stages of soft tissue sarcoma. The advanced healthcare infrastructure of the region is the main driving factor for the growth of the soft tissue sarcoma market in North America. Advanced healthcare facilities, including well-equipped hospitals and specialized cancer treatment centers, have boosted the demand for advanced soft tissue sarcoma treatments. Favorable reimbursement policies for cancer are also prevalent in the region. Treatments have also played a significant role in driving the market growth. In addition, the presence of major market players, such as Pfizer Inc., Eli Lilly and Company, and Johnson & Johnson, in North America has led to the development of advanced soft tissue sarcoma treatments. These companies are continuously investing in research and development activities to introduce innovative and effective treatments for soft tissue sarcoma. However, despite the high share in North American markets, the growth of the market will slow down because of saturating demand in the market and alternative treatments. The regional market will remain at the fore of the global soft tissue sarcoma market because of established healthcare structure and technological advancements.

COVID-19 Impact Analysis on the Global Soft Tissue Sarcoma Market:

The pandemic caused significant disruption in the global soft tissue sarcoma market. Cases often resulted in delayed diagnosis, treatment, and clinical trials. Many hospitals and oncology centers put COVID-19 patients first, resulting in postponed surgery, radiation therapy, and chemotherapy sessions. This indirectly affected patient outcomes. Late-stage detection is also ascribed to reduced access to diagnostic services, reduced survival rate, and disease severity. Supply chain disruptions also resulted in shortages of essential drugs and medical equipment, which complicated treatment further. In addition, fewer patient visits and restrictions on clinical trials slowed the development of new therapies. Telemedicine became an alternative to consultations, but it could not replace critical in-person evaluations and procedures. This holistic effect highlighted a greater need to make healthcare stronger and better manage the interruption in cancer care resulting from global calamities.

Latest Trends/ Developments:

The Soft Tissue Sarcoma Market is witnessing significant advancement, mainly because of ongoing research, innovative therapies, and advanced diagnostic techniques. These advancements focus on improving the outcomes of the patients and the survival rate. Here, we discuss five major recent developments that are changing the face of treatment and management for esophageal cancer. The recent approval of multiple targeted therapies and immunotherapies expanded treatment choices for esophageal cancer patients. Others have been the introduction of trastuzumab deruxtecan, whose preliminary results showed excellent efficacy in HER2-positive cases. Those innovations are very important for improving patient survival rates and providing patients with more alternate treatment options. New techniques in diagnostic technology will improve the diagnostic process of esophageal cancer. Technologies such as advanced endoscopic imaging and liquid biopsies help in identifying precancerous lesions more precisely than before. Early detection is critical because it increases the possibility of successful treatment and a better outcome from the disease. There is an increasing interest in genetic profiling to individualize treatment strategies for esophageal cancer patients. Recent studies have shown that it is essential to identify specific genetic mutations that could influence the treatment response. Through personalization of therapies based on genetic markers, clinicians can maximize the effectiveness of treatment and minimize adverse effects. The esophageal cancer landscape continues to change with the integration of artificial intelligence (AI) in the planning of treatment. Thousands of datasets will be analyzed using the algorithms of AI to help clinicians make informative decisions regarding treatment plans. It can predict patient responses, therefore paving the way to more effective individualized care treatments.

Key Players:

1. Pfizer
2. Eli Lilly
3. Johnson & Johnson
4. GSK(GlaxoSmithKline)
5. Roche
6. Hospira
7. Eisai
8. Bayer